ACM
BLPH

ACT Capital Management’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

ACT Capital Management’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-25,000
Closed -$102K – 122
2021
Q3 		$102K Hold
25,000
– – 0.05% 95
2021
Q2 		$121K Buy
+25,000
New +$112K 0.06% 95

Other funds holding BLPH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACT Capital Management's BLPH Position: Q4 2021 in Review

ACT Capital Management sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q4 2021, closing a stake of 25,000 shares — an estimated $102K sold.

ACT Capital Management first reported a position in BLPH in Q2 2021 and held it in 2 quarters. The position peaked at $121K in Q2 2021. 22 funds tracked by Wall St. Rank hold BLPH as of Q4 2021.

  • ACT Capital Management reported no remaining Bellerophon Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
  • ACT Capital Management sold 25,000 Bellerophon Therapeutics, Inc. shares in Q4 2021, an estimated $102K.
  • ACT Capital Management first reported a position in Bellerophon Therapeutics, Inc. in Q2 2021 and held it in 2 quarters.
  • ACT Capital Management's Bellerophon Therapeutics, Inc. position peaked at $121K in Q2 2021.
  • 22 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q4 2021.

Based on ACT Capital Management's 13F filing for Q4 2021, filed 3 Feb 2022.